Ert Pompe denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Step Therapy to ERT for Pompe Disease

Step-therapy (also called "fail-first") denials require a patient to try and fail a less expensive or preferred therapy before the plan will cover the requested drug. For Pompe disease, this denial is particularly problematic: there is no non-ERT pharmacological option that addresses the underlying enzyme deficiency. When UHC applies a step-therapy requirement here, it typically reflects one of two situations: (1) the plan's policy requires a trial of one specific ERT before authorizing a different (often newer) ERT; or (2) the policy was written for a broader drug class and the rare-disease context was not anticipated.

## Why This Denial Is Appealable

Step-therapy exceptions are legally required in most states and under federal guidance when: the required first-step drug is contraindicated, previously caused an adverse reaction, or was clinically tried and found inadequate. For Pompe disease, if the step-therapy protocol requires a different ERT agent that the patient has already received, or that is not appropriate for the patient's disease subtype, the exception criteria are almost certainly met. Additionally, many states have enacted step-therapy reform laws that prohibit plans from requiring a patient to fail a therapy that was previously tried — verify your state's protections.

## Federal and State Appeal Framework

• ERISA §503 (employer plans): Step-therapy denials are adverse benefit determinations subject to full-and-fair internal appeal.
• ACA §2719: External review is available after internal appeal. An IRO will assess whether applying the step-therapy requirement is clinically appropriate given the rare-disease context.
• The external-review window is generally within approximately four months of denial; check your Explanation of Benefits for the exact date.
• Expedited review is strongly appropriate — Pompe disease progresses during any delay, and the harm from a missed infusion is not reversible.
• State step-therapy laws: Check whether your state has enacted step-therapy exception protections (many now require insurers to honor exceptions for previously tried therapies or contraindicated alternatives).

## Concrete Appeal Steps

1. Obtain UHC's step-therapy policy for this drug — identify which "step-one" therapy the plan requires, and on what clinical basis. 2. Determine whether the step-one therapy was already tried (with inadequate response or adverse effect), is not approved for your disease subtype, or poses a clinical risk — document whichever applies. 3. File for a step-therapy exception at the same time as the internal appeal. 4. If both are denied, proceed to external review and, if applicable, your state insurance commissioner.

## Documentation to Gather

• Prior-therapy history: If the step-one ERT was previously used, provide dates, clinical response measurements, and physician notes explaining why it was discontinued or deemed inadequate.
• Adverse reaction documentation: If the step-one agent caused adverse effects, include the physician note, any pharmacy adverse-event report, and the date the agent was stopped.
• Indication mismatch (if applicable): If the step-one agent is not FDA-approved for the patient's specific Pompe disease subtype, provide the FDA label sections for both agents comparing indications.
• Disease progression risk letter: A letter from the treating specialist explaining that delaying or substituting the prescribed ERT to complete a step-therapy protocol poses a specific, documented clinical risk for this patient.
• Diagnosis and functional status: Genetic confirmation, enzyme assay, and current functional assessments (pulmonary, motor) to establish the urgency of uninterrupted treatment.

## Criteria-Mapping Structure

Step-therapy exception criteria typically include: (1) prior failure of the required step; (2) contraindication or adverse reaction; (3) clinical inappropriateness. Map your facts:

| Exception Criterion | Your Evidence | |---|---| | Prior trial of step-one therapy | Treatment records dated [start–end]; physician note on outcome | | Adverse reaction to step-one | Physician note dated [date]; reaction description; discontinuation decision | | Step-one not approved for this subtype | FDA label comparison: step-one indication vs. patient's confirmed subtype | | Clinical urgency of the prescribed agent | Specialist urgency letter with functional decline data |